Akebia Therapeutics (FRA:AX9) Other Gross PPE: €6.3 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:AX9 Akebia Therapeutics Inc FRA:AX9
46 GF Score
Price €0.80
GF Value €1.03
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Akebia Therapeutics Other Gross PPE?

Akebia Therapeutics FRA:AX9 -0.47% 46 Other Gross PPE is €6.3 Mil as of Jun. 2026. GuruFocus rates FRA:AX9 with a GF Score™ of 46/100 and a GF Value™ of €1.03 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Akebia Therapeutics's Other Gross PPE for the quarter that ended in Jun. 2026 was €6.3 Mil.

Akebia Therapeutics's quarterly Other Gross PPE declined from Dec. 2025 (€4.2 Mil) to Mar. 2026 (€3.0 Mil) but then increased from Mar. 2026 (€3.0 Mil) to Jun. 2026 (€6.3 Mil).

Akebia Therapeutics's annual Other Gross PPE declined from Dec. 2023 (€14.7 Mil) to Dec. 2024 (€9.9 Mil) and declined from Dec. 2024 (€9.9 Mil) to Dec. 2025 (€4.2 Mil).

Akebia Therapeutics Other Gross PPE Historical Data

* Premium members only.

The historical data trend for Akebia Therapeutics's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akebia Therapeutics Other Gross PPE Chart

Akebia Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Gross PPE
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.98 32.45 14.71 9.95 4.17

Akebia Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.68 5.38 4.17 2.96 6.35
FRA:AX9
46GF Score
Akebia Therapeutics Inc FRA:AX9
Other Gross PPE is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Akebia Therapeutics Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Frequently Asked Questions Learn more about Other Gross PPE →
What does a Other Gross PPE of €6.3 Mil mean?
Akebia Therapeutics (FRA:AX9) has a Other Gross PPE of €6.3 Mil as of Jun. 2026. Other Gross PPE is property, plant and equipment recorded on a company's balance sheet that not otherwise classified. View historical data on Akebia Therapeutics and its competitors.
Is Akebia Therapeutics' Other Gross PPE too high?
Akebia Therapeutics' current Other Gross PPE is €6.3 Mil. Overall, Akebia Therapeutics has a GF Score™ of 46/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' Other Gross PPE compare to ORGO and SIGA?
Akebia Therapeutics' Other Gross PPE of €6.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Gross PPE for a Drug Manufacturers company?
A good Other Gross PPE depends on the Drug Manufacturers industry context. However, Other Gross PPE should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Gross PPE mean?
A high Other Gross PPE can signal that a stock is expensive relative to its fundamentals. Other Gross PPE is property, plant and equipment recorded on a company's balance sheet that not otherwise classified. View historical data on Akebia Therapeutics and its competitors. Akebia Therapeutics's current Other Gross PPE is €6.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (FRA:AX9) is currently considered Modestly Undervalued. The stock's GF Value™ is €1.03, compared to a current price of €0.80 — trading 22.3% below its estimated fair value. The current Other Gross PPE is €6.3 Mil. Akebia Therapeutics' overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Gross PPE calculated?
Other Gross PPE is calculated from a company's financial statements. For Akebia Therapeutics (FRA:AX9), the current Other Gross PPE is €6.3 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Akebia Therapeutics (FRA:AX9) Overvalued in 2026?

Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be undervalued. The current stock price of €0.80 is trading 22.3% below its estimated GF Value™ of €1.03. GuruFocus considers Akebia Therapeutics to be Modestly Undervalued.

Key valuation signals for FRA:AX9:

  • Other Gross PPE: €6.3 Mil
  • GF Value™: €1.03 vs. price of €0.80 (22.3% below fair value)
  • GF Score™: 46/100 with 4 warning signs

No single metric tells the full story. See the FRA:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Akebia Therapeutics Business Description

Other Exchanges AKBA:USAAX9:Germany
Address 245 First Street, Suite 1400, Cambridge, MA, USA, 02142
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
46GF Score

Get the complete analysis for FRA:AX9

Other Gross PPE is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.80
Price
€1.03
GF Value